Designing safer glucocorticoid drugs

Glucocorticoid drugs are used widely. However, their long-term use is limited by severe side effects, including high blood levels of glucose, fatty liver, and type 2 diabetes. New research now shows that the protein LXR-beta is required in mice for glucocorticoid drugs to elicit many of their negative side effects, suggesting that glucocorticoid drugs designed to selectively target the glucocorticoid receptor and not LXR-beta should be safer than those currently in clinical use.

Read the whole article on Science Daily

More from Science Daily